Orchestra BioMed Holdings (OBIO) Payables (2020 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Payables of $6.3 million for Q1 2026, up 13.48% year-over-year from $5.6 million in Q1 2025, and up 3.58% quarter-over-quarter from $6.1 million in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Payables (2020 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Payables for 7 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 13.48% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 13.48% YoY), while the FY2025 annual figure was $6.1 million, up 18.72% from the prior year.
- Payables climbed to $6.3 million in Q1 2026 per OBIO's latest filing, from $6.1 million in the prior quarter.
- Across five years, Payables topped out at $8.5 million in Q3 2025 and bottomed at $103607.0 in Q1 2022.
- Historically, Payables has averaged $4.1 million across 5 years, with a median of $4.7 million in 2024.
- Annual changes were most pronounced in 2022 — Payables soared 16912.75% — and 2023, when it plunged 52.12%.
- Orchestra BioMed Holdings' Payables stood at $6.1 million in 2022, then slumped by 52.12% to $2.9 million in 2023, then surged by 77.03% to $5.1 million in 2024, then advanced by 18.72% to $6.1 million in 2025, then climbed by 3.58% to $6.3 million in 2026.
- Business Quant data shows OBIO's Payables at $6.3 million in Q1 2026, $6.1 million in Q4 2025, and $8.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 6.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.13 Mn |
| Mar 31, 2026 | 6.31 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | 8.47 Mn |
| Jun 30, 2025 | 5.31 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 5.13 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 6.27 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 2.77 Mn |
| Dec 31, 2022 | 6.06 Mn |
| Sep 30, 2022 | 281,561.00 |
| Jun 30, 2022 | 170,657.00 |
| Mar 31, 2022 | 103,607.00 |
| Dec 31, 2021 | 1,388.00 |
| Sep 30, 2021 | 1,655.00 |